2026-11-12

Platform FAQ | AlfaCell Frequently Asked Questions (Business Edition)

2026-11-09

Event Recap | Great Bay Bio Successfully Concludes Its 2nd Technical Seminar on Site-Specific Integration for Cell Line Development

2026-11-04

Platform FAQ | AlfaCell Frequently Asked Questions (Case Studies Edition)

2026-11-02

Event Recap | Great Bay Bio Showcases AI-Driven Innovation at CHIPS 2026, Advancing the Biopharmaceutical Industry

2026-10-27

Event Recap | Great Bay Bio Co-Hosts Two Forums at BioCMC 2026

2026-09-23

Platform FAQ | AlfaCell Frequently Asked Questions (Technical Edition)

2026-09-04

Platform Case Study | Fat Loss Without Muscle Loss: AlfaDAX Powers End-to-End ActRII Antibody Development, with Research Findings Published on bioRxiv

2026-08-12

Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026

2026-08-07

AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel

2026-07-17

Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published